2023, Vol. 5, Issue 4, Part A

Aim: To study the levels of serum Lipoprotein (a) in patients with angiographically proven coronary artery disease.

Methodology: This is a Cross-sectional, Hospital based study conducted at Medicover Hospital which is a tertiary care center situated in the capital of Telangana, Hyderabad. The study was conducted after obtaining approval from scientific and ethical committee of the hospital. Written and informed consent taken from all the patients and from the next of kin if the patient clinically not in a position to give consent. Study population includes patients admitted to Medicover Hospital MICU, ICCU, who are full filling the inclusion and exclusion criteria are included in our study.

Results: Lipoprotein (a) levels were higher in younger age group (≤ 55 years).Lipoprotein (a) levels were higher in patients with family history of coronary artery disease. Lipoprotein (a) levels were higher in patients with elevated LDL levels. Serum Lipoprotein (a) levels correlate directly with angiographic evidence of extent and severity of coronary artery disease. Lipoprotein (a) levels were higher in Triple vessel and Double vessel disease. Lipoprotein (a) is an emerging risk factor for coronary artery disease. There is no significant difference in Mean Lp (a) levels among Diabetics and Non Diabetics.

Conclusion: Lp (a) is associated with occurrence and extent of coronary stenosis we suggest that it should be screened in all young individuals with coronary artery disease without risk factors, familial hypercholesterolemia, family history of premature cardiovascular disease and/or elevated Lp (a), and individuals with recurrent cardiovascular disease. Lp (a) should be measured routinely in the coronary risk profile assessment of high-risk patients.